Ozempic is semaglutide (GLP-1). Mounjaro is tirzepatide (GLP-1/GIP dual agonist). They are not the same pen with a different label. Canadian clinicians choose based on indication, supply, tolerance, comorbidities, and cost — not TikTok rankings.
| Factor | Ozempic | Mounjaro |
|---|---|---|
| Molecule | Semaglutide (GLP-1) | Tirzepatide (GLP-1/GIP) |
| Common patient search | Diabetes + weight interest | Weight + metabolic interest |
| Class GI effects | Nausea, fullness, etc. | Similar class GI effects |
| BC access | Widely discussed in clinics | Discuss with clinic for current availability |
Effectiveness conversations
Trial literature often shows substantial weight change with both classes when combined with lifestyle support; head-to-head marketing claims are not a substitute for your chart. A BC clinic should set expectations for your BMI, meds, and titration pace.
Side effects
Both can cause GI symptoms during escalation. Emergency vs clinic callback: side effects guide (principles overlap for GLP-1-class drugs; follow your prescriber’s instructions for tirzepatide specifically).
Cost
Cash prices fluctuate. Budget for medication + follow-ups. Coverage for obesity-only use is limited — PharmaCare guide · cost overview.
When clinics prefer one pathway
- Prior response or intolerance to semaglutide
- Diabetes vs primary weight-management indication
- Supply and provincial formulary realities
- Patient preference after informed consent
Explore Mounjaro clinics BC · Ozempic Vancouver · Ozempic vs Wegovy.
Free clinic callback
Stay on this site. A partner clinic can call you. Free for patients.
Educational only. Not medical advice. Licensed clinicians decide treatment. Results vary.